These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9507699)

  • 1. Synthesis and antitumor activity of [1,2-bis(4-fluorophenyl)ethylenediamine][dicarboxylato]platinum(II) complexes.
    Gust R; Krauser R; Schmid B; Schönenberger H
    Arch Pharm (Weinheim); 1998 Jan; 331(1):27-35. PubMed ID: 9507699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability and cellular studies of [rac-1,2-bis(4-fluorophenyl)-ethylenediamine][cyclobutane-1,1- dicarboxylato]platinum(II), a novel, highly active carboplatin derivative.
    Gust R; Schnurr B; Krauser R; Bernhardt G; Koch M; Schmid B; Hummel E; Schönenberger H
    J Cancer Res Clin Oncol; 1998; 124(11):585-97. PubMed ID: 9860287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and cytotoxicity of enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)-3-methylbutane]platinum(II) complexes.
    Dullin A; Dufrasne F; Gelbcke M; Gust R
    ChemMedChem; 2006 Jun; 1(6):644-53. PubMed ID: 16892405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a parenterally administrable hydrosol preparation of the "third generation platinum complex" [(+/-)-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activity.
    Gust R; Bernhardt G; Spruss T; Krauser R; Koch M; Schönenberger H; Bauer KH; Schertl S; Lu Z
    Arch Pharm (Weinheim); 1995 Sep; 328(9):645-53. PubMed ID: 7487421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor inhibiting [1,2-bis(difluorophenyl)ethylenediamine]dichloroplatinum (II) complexes, I: Synthesis.
    Müller R; Schickaneder E; Jennerwein M; Reile H; Spruss T; Engel J; Schönenberger H
    Arch Pharm (Weinheim); 1991 Feb; 324(2):115-20. PubMed ID: 1854235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mono- and polynuclear [alkylamine]platinum(II) complexes of [1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II): synthesis and investigations on cytotoxicity, cellular distribution, and DNA and protein binding.
    Kapp T; Dullin A; Gust R
    J Med Chem; 2006 Feb; 49(3):1182-90. PubMed ID: 16451082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinum(II) oxalato complexes with adenine-based carrier ligands showing significant in vitro antitumor activity.
    Starha P; Trávnícek Z; Popa I
    J Inorg Biochem; 2010 Jun; 104(6):639-47. PubMed ID: 20304500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antitumor activity of enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)propane]dichloroplatinum(II) complexes.
    Dufrasne F; Gelbcke M; Schnurr B; Gust R
    Arch Pharm (Weinheim); 2002 May; 335(5):229-39. PubMed ID: 12210780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) complexes.
    Kim DK; Kim G; Gam J; Cho YB; Kim HT; Tai JH; Kim KH; Hong WS; Park JG
    J Med Chem; 1994 May; 37(10):1471-85. PubMed ID: 8182706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [N-ethyl- and [N,N'-diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II): structure and cytotoxic/estrogenic activity in breast cancer cells.
    Gust R; Niebler K; Schönenberger H
    J Med Chem; 2005 Nov; 48(23):7132-44. PubMed ID: 16279771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological properties.
    Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
    Arch Pharm (Weinheim); 1989 Feb; 322(2):67-73. PubMed ID: 2730292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical stability, biological activity and cellular uptake of a cisplatin analogue having a 1,2-diarylethyleneamine ligand in cultures of human breast cancer cells.
    Otto AM; Kratochwil NA; Eggers H; Bednarski PJ
    J Cancer Res Clin Oncol; 1995; 121(1):31-8. PubMed ID: 7860616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure activity studies on leaving group derivatives of [meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] platinum(II).
    Gust R; Keilitz R; Krauser R; Schmidt K; Schnurr B
    Arch Pharm (Weinheim); 1999 Aug; 332(8):261-70. PubMed ID: 10489536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
    Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
    J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2001 Oct; 334(10):309-17. PubMed ID: 11759169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: Synthesis.
    Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
    Arch Pharm (Weinheim); 1989 Jan; 322(1):25-9. PubMed ID: 2730286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.
    Karl J; Gust R; Spruss T; Schneider MR; Schönenberger H; Engel J; Wrobel KH; Lux F; Haeberlin ST
    J Med Chem; 1988 Jan; 31(1):72-83. PubMed ID: 3336035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrepancy between cytotoxicity, platinum accumulation, and DNA platination in MCF-7 breast cancer cells treated with diaqua (1,2-diphenylethylenediamine) platinum (II) sulfates and cisplatin.
    Lux F; Hollstein M; Reile H; Bernhardt G; Schönenberger H
    Biol Trace Elem Res; 1996; 53(1-3):113-28. PubMed ID: 8862742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
    Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
    J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum(II)-dendrimer conjugates: synthesis and investigations on cytotoxicity, cellular distribution, platinum release, DNA, and protein binding.
    Kapp T; Dullin A; Gust R
    Bioconjug Chem; 2010 Feb; 21(2):328-37. PubMed ID: 20104885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.